Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma.

Cell reports - 31 Oct 2023

Xu Yuewei, Spear Sarah, Ma Yurui, Lorentzen Marc P, Gruet Michael, McKinney Flora, Xu Yitao, Wickremesinghe Chiharu, Shepherd Madelen R, McNeish Iain, Keun Hector C, Nijhuis Anke

Abstract excerpt

Ovarian high-grade serous carcinoma (HGSC) is the most common subtype of ovarian cancer with limited therapeutic options and a poor prognosis. In recent years, poly-ADP ribose polymerase (PARP) inhibitors have demonstrated significant clinical benefits, especially in patients with BRCA1/2 mutations. However, acquired drug resistance and relapse is a major challenge. Indisulam (E7070) has been identified as a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Recurrence, Local

Share to Phthalazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to RNA Splicing

Share to RNA Splicing Factors

Source

Identifiers

PMID: 37858464
DOI: 10.1016/j.celrep.2023.113307

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma.PMID 37858464Read ↗

Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinomaSemantic proximity Read ↗

Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15.Semantic proximity Read ↗

Indisulam exerts anticancer effects on human cervical carcinoma cells via induction of aberrant splicing, cycle arrest, and apoptosisSemantic proximity Read ↗

A molecular glue RBM39-degrader induces synthetic lethality in cancer cells with homologous recombination repair deficiencySemantic proximity Read ↗

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitorsSemantic proximity Read ↗

Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degradersSemantic proximity Read ↗

Targeting the spliceosome through RBM39 degradation results in exceptional responses in high-risk neuroblastoma modelsSemantic proximity Read ↗

MicroRNA320e augments the synthetic lethality of olaparib by regulating homologous recombination repair via PI3K-AKT-mTOR pathwaySemantic proximity Read ↗

YAP/TAZ interacts with RBM39 to confer resistance against indisulamSemantic proximity Read ↗

Targeting RRM2 Enhances PARP Inhibitor Efficacy in Ovarian Cancer CellsSemantic proximity Read ↗

Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian CancerSemantic proximity Read ↗

MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOCSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.